Amarantus Reports First Quarter 2015 Financial Results and Business Overview
May 20, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
- Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -
- Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT -
SAN FRANCISCO and...
Amarantus to Present at Two Upcoming Investor Conferences
May 19, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
-Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT-
-LD Micro Invitational Presentation and Webcast on June 2, 2015, at 1:30 p.m. EDT / 10:30 a.m....
Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
May 15, 2015 08:05 ET
|
Amarantus BioScience Holdings, Inc.
Collaboration Using Renishaw Plc's Convection-Enhanced Delivery Device Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas
Delivery and Distribution Data Solidifies...
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015 08:05 ET
|
Amarantus BioScience Holdings, Inc.
- Catalent to Utilize Proprietary GPEx® Platform for Production of High Performance MANF Expressing Cell Line -
- cGMP Production of MANF to Enable Program Advancement Into Human Clinical...
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease
May 13, 2015 13:00 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, Switzerland, May 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic...
Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
May 11, 2015 08:35 ET
|
Amarantus BioScience Holdings, Inc.
-MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis-
-Data supports further research into blood-based...
Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 07, 2015 11:15 ET
|
Amarantus BioScience Holdings, Inc.
- Study conducted by leading researchers at University of Miami -
- Data demonstrate MANF preserves photoreceptor cells and light-sensing function -
SAN FRANCISCO and GENEVA, May 7, 2015 (GLOBE...
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 05, 2015 08:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
April 29, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, April 29, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
Amarantus Closes $5 Million Preferred Stock Financing
April 27, 2015 07:05 ET
|
Amarantus BioScience Holdings, Inc.
SAN FRANCISCO and GENEVA, April 27, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic...